nirmatrelvir and ritonavir drug combination

Also Known As:

PF-07321332 and ritonavir drug combination; PF-07321332, ritonavir; PF-07321332, ritonavir drug combination; Paxlovid; nirmatrelvir, ritonavir; nirmatrelvir, ritonavir drug combination

Networked: 471 relevant articles (50 outcomes, 72 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Pharmaceutical Preparations
- Drug Combinations: 5337
  - nirmatrelvir and ritonavir drug combination: 471
Organic Chemicals: 133
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Lactams: 2198
    - nirmatrelvir and ritonavir drug combination: 471
  - Azoles: 2138
    - Thiazoles: 392
      - Ritonavir: 2167
        nirmatrelvir and ritonavir drug combination: 471
Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675

Experts

1.	Bassani, Davide: 2 articles (12/2022 - 12/2022)
2.	Eyal, Sara: 2 articles (12/2022 - 01/2022)
3.	Moro, Stefano: 2 articles (12/2022 - 12/2022)
4.	Pavan, Matteo: 2 articles (12/2022 - 12/2022)
5.	Sturlese, Mattia: 2 articles (12/2022 - 12/2022)
6.	Brown, Robert S: 2 articles (11/2022 - 01/2022)
7.	Chen, Justin K: 2 articles (11/2022 - 01/2022)
8.	Hedvat, Jessica: 2 articles (11/2022 - 01/2022)
9.	Jennings, Douglas L: 2 articles (11/2022 - 01/2022)
10.	Lange, Nicholas W: 2 articles (11/2022 - 01/2022)

Related Diseases

1.	COVID-19 05/01/2023 - "Conclusion This study suggests that Paxlovid is highly effective in reducing the risk of severe COVID-19 or mortality. " 01/01/2023 - "This study suggests that in the era of Omicron and in real-life settings, Paxlovid is highly effective in reducing the risk of severe COVID-19 or mortality." 09/04/2023 - "Nirmatrelvir-ritonavir is highly effective in preventing severe coronavirus disease 2019 (COVID-19) in high-risk patients with mild-to-moderate severity. " 01/01/2023 - "The efficacy of Nirmatrelvir/Ritonavir in the treatment of the Omicron variant of COVID-19 was positive and had good tolerance in patients." 01/01/2023 - "A randomized controlled trial involving a high-risk, unvaccinated population that was conducted before the Omicron variant emerged found that nirmatrelvir-ritonavir was effective in preventing progression to severe COVID-19. "
2.	Infections 10/15/2023 - "Nirmatrelvir/ritonavir is a highly efficacious agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. " 11/01/2023 - "This target trial emulation study aimed to address this gap by evaluating the use of nirmatrelvir/ritonavir in nonhospitalized pregnant women with symptomatic SARS-CoV-2 Omicron variant infection. " 11/01/2023 - "Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation." 11/01/2023 - "The findings suggest that nirmatrelvir/ritonavir is an effective treatment in symptomatic pregnant women with SARS-CoV-2 Omicron variant infection." 09/20/2023 - "Among those who took a long course of nirmatrelvir/ritonavir outside of the context of an acute infection, some experienced a meaningful reduction in symptoms, although not all benefits persisted; others experienced no effect on symptoms. "
3.	Pneumonia (Pneumonitis) 01/01/2023 - "Oral treatment with nirmatrelvir/ritonavir in high-risk non-hospitalized patients was safe and effective in preventing the severe clinical progress of COVID-19 pneumonia. " 01/01/2023 - "Paxlovid and immunoglobulins improved the prognosis of patients with severe pneumonia. " 05/09/2023 - "Only 11 patients (overall rate of 2.8%) developed severe COVID-19-associated pneumonia requiring admission to hospital: 8 controls (7.2%); 2 patients on Nirmatrelvir/Ritonavir (2.0%); and 1 on Sotrovimab (1.8%). " 09/06/2023 - "Successful treatment of a case of COVID-19 pneumonia following kidney transplantation using paxlovid and tocilizumab." 10/28/2023 - "This study aimed to evaluate the effect of administering nirmatrelvir/ritonavir and molnupiravir before hospitalisation on subsequent critical illness among patients with COVID-19 pneumonia. "
4.	Critical Illness (Critically Ill) 10/15/2023 - "To characterise the features of nirmatrelvir/ritonavir in critically ill Chinese patients undergoing CRRT, therapeutic drug monitoring of nirmatrelvir/ritonavir was performed by high-performance liquid chromatography tandem mass spectrometry assay in eight patients. " 07/10/2023 - "Paxlovid treatment in patients aged ≥ 60 years of age was associated with significantly reduced risk of severe/critical illness or death (46.0%), and death rate (32.5%), and its effectiveness was high, regardless of vaccination status. " 10/15/2023 - "High concentrations of nirmatrelvir/ritonavir in critically ill patients receiving continuous renal replacement therapy." 07/10/2023 - "This study assessed the effectiveness of Paxlovid at reducing the risk of severe/critical illness or death and death in patients with mild-to-moderate COVID-19 caused by omicron subvariant BA.5. In this nationwide retrospective cohort study, data on 8,902,726 patients were collected from four sources (the Drug Utilization Review database, COVID-19 Patient Information Management System, confirmed patient information, and basic epidemiological investigation data) between July 1 and November 30, 2022. " 10/28/2023 - "No significant differences in critical illness were observed between molnupiravir and nirmatrelvir/ritonavir. "
5.	Post-Acute COVID-19 Syndrome 11/11/2023 - "Our finding that treatment with nirmatrelvir/ritonavir was not associated with a lower risk of developing long COVID is different from prior studies that obtained data only from electronic medical records." 11/11/2023 - "We found that participants who took nirmatrelvir/ritonavir were no less likely to develop long COVID symptoms, compared to those who did not take the medication (44% vs. 49.6%, p = 0.21). " 11/11/2023 - "We conducted a retrospective cohort study to assess whether treatment with nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. " 11/11/2023 - "Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study." 10/01/2023 - "Nirmatrelvir/ritonavir as a possible treatment for Long-COVID."

Related Drugs and Biologics

1.	nirmatrelvir and ritonavir drug combination
2.	molnupiravir
3.	Antiviral Agents (Antivirals)
4.	remdesivir
5.	Ritonavir (Norvir)
6.	nirmatrelvir
7.	sotrovimab
8.	azvudine
9.	Peptide Hydrolases (Proteases)
10.	Vaccines

Related Therapies and Procedures

1.	Therapeutics
2.	Renal Dialysis (Hemodialysis)
3.	Oral Administration
4.	Length of Stay
5.	Aftercare (After-Treatment)